{"id":15472,"date":"2026-02-11T10:36:58","date_gmt":"2026-02-11T10:36:58","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&#038;p=15472"},"modified":"2026-04-08T14:53:32","modified_gmt":"2026-04-08T14:53:32","slug":"storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/","title":{"rendered":"STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months"},"content":{"rendered":"\n<h2 class=\"wp-block-heading has-text-2-xl-font-size\">A Connected Approach to Complex Discovery <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Drug discovery moves quickly, and complex biology demands both speed and precision. STORM Therapeutics partnered with Sygnature Discovery to advance their DHX9 inhibitor program with the goal of delivering a best in class pre-clinical development candidate within two years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Our teams built a fully integrated discovery plan that united chemistry, biology and data driven decision making from day one. Through close collaboration, rapid iteration and diverse hit finding strategies, Sygnature identified multiple unique small molecule hits and advanced the program from lead to pre candidate in just 18 months. This result exceeded typical industry expectations and demonstrated the power of connected discovery.<\/p>\n\n\n\n<div class=\"wp-block-group alignfull is-style-default has-ivory-000-color has-text-color has-background is-layout-flow wp-block-group-is-layout-flow\" style=\"border-radius:1.5em;background:linear-gradient(90deg,rgb(0,60,97) 0%,rgb(4,30,46) 100%);margin-top:var(--wp--preset--spacing--40);margin-bottom:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--50);padding-left:var(--wp--preset--spacing--50)\" allowchildrentofillwidth=\"\" overflow=\"\" flexwrap=\"\">\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center has-small-font-size wp-block-paragraph\" style=\"line-height:.9\"><strong>CASE STUDY<\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-xl-font-size\" id=\"schedule-a-visit\" style=\"line-height:1.15\">See the complete project timeline, scientific insight and multidisciplinary approach that accelerated this program.<\/h4>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-dd0a6548 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-50\" modaltype=\"\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/dhx9-inhibitor-case-study-sygnature-discovery.pdf\">Download<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-xl-font-size\">About STORM Therapeutics <\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">STORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME) has led to the discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">STORM\u2019s lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 1b\/2 study in combination with LOQTORZI<sup>\u00ae<\/sup>, (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, in patients with NSCLC, HNSCC, melanoma, and endometrial cancer. Further information is available at&nbsp;<a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06975293\">www.clinicaltrials.gov<\/a>&nbsp;NCT identifier: NCT06975293.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading has-text-xl-font-size\">About Sygnature Discovery<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Sygnature Discovery is a world-leading integrated drug discovery contract research organization, based in the UK and Canada, with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of close to 900 employees, including 700+ scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature has delivered 61 novel pre-clinical compounds, 38 of which have already progressed to clinical trials. Two have reached major milestones: one has been approved, and another is under regulatory review. Our scientists are named on more than 235 patents and our therapeutic areas of expertise span oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Accelerating a best in class DHX9 inhibitor ahead of industry timelines.<\/p>\n","protected":false},"featured_media":15486,"template":"","category":[1402,690,691,678,692,751,688],"resource_tag":[],"class_list":["post-15472","case-study","type-case-study","status-publish","has-post-thumbnail","hentry","category-direct-to-biology","category-hit-identification","category-hit-to-lead","category-integrated-drug-discovery","category-lead-optimisation","category-oncology","category-therapeutic-areas"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DHX9 Inhibitor Case Study | Sygnature Discovery<\/title>\n<meta name=\"description\" content=\"See how connected teams advanced a DHX9 program from lead to pre candidate nomination in less than half the industry timeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DHX9 Inhibitor Case Study | Sygnature Discovery\" \/>\n<meta property=\"og:description\" content=\"See how connected teams advanced a DHX9 program from lead to pre candidate nomination in less than half the industry timeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T14:53:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/dhx9-case-study-cover-sygnature-discovery.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1001\" \/>\n\t<meta property=\"og:image:height\" content=\"588\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/\",\"name\":\"DHX9 Inhibitor Case Study | Sygnature Discovery\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/dhx9-case-study-cover-sygnature-discovery.webp\",\"datePublished\":\"2026-02-11T10:36:58+00:00\",\"dateModified\":\"2026-04-08T14:53:32+00:00\",\"description\":\"See how connected teams advanced a DHX9 program from lead to pre candidate nomination in less than half the industry timeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/dhx9-case-study-cover-sygnature-discovery.webp\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/dhx9-case-study-cover-sygnature-discovery.webp\",\"width\":1001,\"height\":588,\"caption\":\"Cover graphic for the DHX9 inhibitor case study showing the title From Lead to Pre Candidate Nomination in 18 Months with STORM Therapeutics and Sygnature Discovery branding.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DHX9 Inhibitor Case Study | Sygnature Discovery","description":"See how connected teams advanced a DHX9 program from lead to pre candidate nomination in less than half the industry timeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/","og_locale":"fr_CA","og_type":"article","og_title":"DHX9 Inhibitor Case Study | Sygnature Discovery","og_description":"See how connected teams advanced a DHX9 program from lead to pre candidate nomination in less than half the industry timeline.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/","og_site_name":"Sygnature","article_modified_time":"2026-04-08T14:53:32+00:00","og_image":[{"width":1001,"height":588,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/dhx9-case-study-cover-sygnature-discovery.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/","name":"DHX9 Inhibitor Case Study | Sygnature Discovery","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/dhx9-case-study-cover-sygnature-discovery.webp","datePublished":"2026-02-11T10:36:58+00:00","dateModified":"2026-04-08T14:53:32+00:00","description":"See how connected teams advanced a DHX9 program from lead to pre candidate nomination in less than half the industry timeline.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/dhx9-case-study-cover-sygnature-discovery.webp","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/dhx9-case-study-cover-sygnature-discovery.webp","width":1001,"height":588,"caption":"Cover graphic for the DHX9 inhibitor case study showing the title From Lead to Pre Candidate Nomination in 18 Months with STORM Therapeutics and Sygnature Discovery branding."},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/storm-therapeutics-from-lead-to-pre-candidate-nomination-in-18-months\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/15472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/case-study"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/15472\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/15486"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=15472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=15472"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=15472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}